Medarex at peer perform by Thomas Weisel

Medarex Inc. was given an initial research coverage rating at peer perform by Thomas Weisel Partners analyst Joe Slavinsky based on the company's technology and vast pipeline. The company has 10 products in phase 2/3 testing related to fully human antibodies. Shares of the Princeton, N.J., biopharmaceutical company were down 5 cents, or 0.36%, at $13.89 on volume of 1,518,418 shares versus the three-month running average of 1,283,690 shares. (Nasdaq: MEDX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.